www.fdanews.com/articles/193284-kadmons-wilsons-disease-generic-treatment-earns-fda-approval
Kadmon’s Wilson’s Disease Generic Treatment Earns FDA Approval
October 31, 2019
The FDA granted the go-ahead for Kadmon’s Clovique (trientine hydrochloride), a branded generic for treating Wilson’s disease in patients intolerant to penicillamine.
It is the first agency-approved trientine product available in a portable blister pack that offers room temperature stability for up to 30 days.
Wilson’s disease, also known as hepatolenticular degeneration, is a very rare, treatable disease that prevents patients’ bodies from eliminating copper properly, allowing the metal to accumulate to potentially life-threatening levels.